Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial

Rivaroxaban demonstrates efficacy comparable to LMWH in patients with lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery, while exhibiting a superior safety profile compared to LMWH.